OSU-T315 (15-regioisomer)
CAS No. 2070015-22-2
OSU-T315 (15-regioisomer)( ILK-IN-2 )
Catalog No. M20219 CAS No. 2070015-22-2
OSU-T315 (15-regioisomer) is a ILK inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 132 | In Stock |
|
| 5MG | 222 | In Stock |
|
| 10MG | 357 | In Stock |
|
| 25MG | 614 | In Stock |
|
| 50MG | 872 | In Stock |
|
| 100MG | 1161 | In Stock |
|
| 500MG | 2367 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOSU-T315 (15-regioisomer)
-
NoteResearch use only, not for human use.
-
Brief DescriptionOSU-T315 (15-regioisomer) is a ILK inhibitor.
-
DescriptionOSU-T315 (15-regioisomer) is a ILK inhibitor.
-
In VitroOSU-T315 (Compound 22; 0-5 μM; 24 hours) exhibits high in vitro potency against a panel of prostate and breast cancer cell lines with a IC50 range of 1-2.5 μM.?OSU-T315 (0-2.5 μM; 24 hours) can reduce YB-1, HER2, and EGFR expression; shows a modest suppressive effect on phosphorylated S6 levels, exhibits dose-dependent suppressive effects on the levels of phospho-ERK1/2 and phospho-p38, while that of phospho-JNK remains unaltered in PC-3 cell. OSU-T315 (0-4 μM; 24 hours) causes autophagy through ILK inhibition. Western Blot Analysis Cell Line:PC-3 cells; MDA-MB-231 cells Concentration:1 μM, 2 μM, 3 μM, 4 μM; 0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM Incubation Time:24 hours Result:Exhibited a dose-dependent decreasing effect on the phosphorylation of pS6, ERKs, and p38 in PC-3 cells and MDA-MB-231 cells.Cell Viability Assay Cell Line:Prostate cancer cells: LNCaP, PC-3; breast cancer cells: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7; PrEC and MEC cells Concentration:0-5 μM Incubation Time:24 hours Result:Suppressed cancer cells viability in breast and prostate cancer cells (IC (50), 1-2.5μM).Apoptosis Analysis Cell Line:PC-3 cells Concentration:1 μM, 2 μM, 3 μM, 4 μM Incubation Time:24 hours Result:Induced accumulation of LC3-II and PARP cleavage.
-
In VivoOSU-T315 (Oral gavage; 25 mg/kg, 50 mg/kg; single daily; 35 days) has a suppressive effect of on PC-3 xenograft tumor growth . No other obvious toxicity is observed in mice. Animal Model: Male NCr athymic nude mice with PC-3 tumor xenografts Dosage:25 mg/kg; 50 mg/kg Administration:Oral gavage; single daily; 35 days Result:Resulted in suppression of tumor growth relative to the vehicle control after 35 days of treatment (48% and 62% suppression for 25 and 50 mg/kg, respectively).
-
SynonymsILK-IN-2
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorILK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2070015-22-2
-
Formula Weight533.6
-
Molecular FormulaC30H30F3N5O
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL?(93.70 mM)
-
SMILESCNC(=O)CCc1cc(nn1-c1ccc(cc1)N1CCNCC1)-c1ccc(cc1)-c1ccc(cc1)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lee SL et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem. 2011 Sep 22;54(18):6364-74.
molnova catalog
related products
-
Cilengitide
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
-
PLN-1474
PLN-1474 is a potent αVβ1 inibitor with IC50 < 50nM (WO2021127483, compound 1)
-
P11
Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic.
Cart
sales@molnova.com